Avicenna.AI Raises $10M Series A Funding
Summary
The company intends to use the funds to scale up deployment of its solutions across the world and to diversify its offering into new areas of medicine. Co-founded by Cyril Di Grandi, and Dr. Peter Chang, Avicenna.AI provides healthcare AI solutions that use deep learning to identify, detect and quantify life-threatening pathologies from CT medical images. The company’s business model is based on an asset-light, R&D powerhouse expertise, generating rapid business growth potential through already signed commercial partnerships with leading market actors in the US, Europe and Asia. In parallel, Avicenna’s R&D efforts will add to the four FDA and six CE mark approvals already awarded to its products. The company’s FDA-cleared and CE-Marked tools for neurovascular and thoraco-abdominal pathologies are integrated within the clinical workflow, automatically triggering and reporting algorithm results through the systems already used by radiologists.
Funding
Review available funding amount, funding date, investors, and linked company information related to Avicenna.AI Raises $10M Series A Funding in the interactive ISVWorld profile.